Abdi İbrahim İlaç

İlaç Sanayi

Sosyal ve Yan Haklar

  • -

Çalışma Saatleri


Kuruluş Yılı



Abdi İbrahim Tower Maslak / İSTANBUL Abdi İbrahim Üretim Tesisi Esenyurt / İSTANBUL

Çalışan Sayısı

Beyaz Yaka : 3000-3999

Mavi Yaka : 550-749

Web Site



Abdi İbrahim, Turkish pharmaceutical industry leader, was founded in 1912 in Küçükmustafapaşa, Istanbul at a small pharmacy, by Pharmacist Abdi İbrahim Bey who had started the “healing” journey. Abdi İbrahim has the largest product portfolio in the sector, exceeding 180 brands and approximately 350 products by developing its own products as well as working with 30 licensors. With a powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has been the leader of Turkey’s Pharmaceutical Industry since 2003. Today, Abdi İbrahim, which operates in eight countries outside Turkey, exports to 50 countries ranging from Canada to European Union member states, from North Africa to Asia and creates the highest employment with nearly 3.500 qualified employees in the Turkish pharmaceutical industry. The company also comes to the fore with its marketing and sales team, which is the largest in the industry. Abdi İbrahim, having the first accredited R&D center in the industry, is a role model with its technological equipment and architecture as well as R&D processes in healing the future. Owning four production facilities as AbdiBio, the biotechnological pharmaceuticals production facility that will be completed in 2017 along with its current production facilities in Kazakhstan, Algeria and İstanbul, the company is on a fast track to become a strong international player with its strategic alliances. Abdi İbrahim has taken an important step by signing United Nations Global Principles Agreement in 2010 and given the opportunity to share high standards which it has acquired in the fields of human rights, as well as environmental and social responsibility. Besides, Abdi İbrahim has focused its activities on sustainability studies on level A of Global Reporting Initiative (GRI) and published its second Sustainability Report.